Why the study?
Does pharmaceutical intervention affect the lipid profile in women with polycystic ovary syndrome?
Does pharmaceutical intervention affect the lipid profile in women with polycystic ovary syndrome?
Dyslipidemia is a common cardiometabolic risk factor in PCOS that requires consideration during pharmaceutical treatment.
Answers are grounded in this paper and cite their sources.
May warrant lipid consideration in PCOS care; leaves open need for RCTs on cardiovascular outcomes.
The polycystic ovary syndrome (PCOS), a prevalent endocrinopathy of women, has been associated with a clustering of adverse metabolic features, which co-exist with reproductive dysfunction. Lipid abnormalities are very common in lean as well as obese women with PCOS and should be cautiously considered in the therapeutic management of the syndrome. Clinicians should also critically assess the lipidemic effect of pharmaceutical intervention, primarily aimed at hyperandrogenism, anovulation or insulin resistance. Because dyslipidemia may contribute to long-term cardiometabolic and reproductive sequelae in PCOS, it should be considered as an additional therapeutic target when these patients are assigned to appropriate pharmaceutical treatment.
No takes yet. Share an insight, caveat, or question.
Diamanti‐Kandarakis et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: